Oyster Point Pharma (NASDAQ:OYST) Issues Quarterly Earnings Results

Share on StockTwits

Oyster Point Pharma (NASDAQ:OYST) announced its quarterly earnings data on Tuesday. The company reported ($8.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($7.59), Fidelity Earnings reports.

Shares of NASDAQ OYST opened at $17.49 on Wednesday. Oyster Point Pharma has a 12 month low of $13.26 and a 12 month high of $19.01.

A number of equities research analysts recently commented on the company. JPMorgan Chase & Co. started coverage on Oyster Point Pharma in a report on Monday, November 25th. They set an “overweight” rating and a $26.00 target price for the company. Cowen began coverage on shares of Oyster Point Pharma in a research note on Monday, November 25th. They set an “outperform” rating and a $40.00 price objective for the company. Finally, Piper Jaffray Companies started coverage on shares of Oyster Point Pharma in a report on Monday, November 25th. They issued an “overweight” rating and a $35.00 price objective on the stock.

In other Oyster Point Pharma news, major shareholder Healthcare Strategic Growt Kkr acquired 155,000 shares of the business’s stock in a transaction dated Monday, November 4th. The stock was acquired at an average cost of $17.02 per share, for a total transaction of $2,638,100.00. Also, insider John Snisarenko acquired 3,000 shares of the business’s stock in a transaction dated Monday, November 4th. The stock was acquired at an average price of $17.02 per share, with a total value of $51,060.00. Over the last ninety days, insiders have bought 787,800 shares of company stock valued at $12,438,256.

Oyster Point Pharma Company Profile

Oyster Point Pharma, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ocular surface diseases in the United States. It is involved in developing OC-01, a nicotinic acetylcholine receptor agonist that is in Phase IIb clinical trial to treat the signs and symptoms of dry eye disease, as well as Phase III clinical trial for the neurotrophic keratitis.

Read More: Why is the LIBOR significant?

Receive News & Ratings for Oyster Point Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oyster Point Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.